Moderna, Inc. withdrew its application for a COVID-19 and Influenza combination vaccine for adults aged 50+ but plans to resubmit after receiving efficacy data from an ongoing trial. The delay reflects increased regulatory scrutiny in the U.S.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing